Technology ID

CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus

Lead Inventor
Tripp, Ralph (CDC)
Anderson, Larry (CDC)
Brown, Michael (CDC)
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Lead IC
CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are currently unavailable. CD40 ligand (CD40L, also known as CD154) is an important costimulatory molecule found on the T-cell and is critical for the development of immunity. CD40L may provide a novel adjuvant to enhance cytokine and antibody response to RSV, directing a subject's immune response further towards Th1-mediated outcomes rather than a less effective Th2-type response. This Th2-type response has been previously suggested as the cause of previous live-RSV vaccine failures. This technology, appropriately developed and integrated into an RSV vaccination agenda, may be useful in improving the efficacy of current or future RSV vaccines.
Commercial Applications
  • Improvements to current RSV vaccines
  • Public health vaccination programs
  • Enhancing antibody response and T-cell costimulation for targeted immunogenic outcomes
  • Pharma development programs focusing on care for neonates, children and the elderly
Competitive Advantages
  • Increased expression of Th1-type cytokines and antibody production
  • Enhanced CD40 costimulation
  • May overcome prior live-RSV vaccine issues (which generated a primarily Th2-type immune response) by steering post-vaccination immunity further towards a preferred Th1-type (IL-2 and IFN-gamma) response, enhancing virus clearance in vivo
Licensing Contact:
Specialist (ALS), Admin. Licensing